Table 1 Baseline Characteristics.

From: Procedural complication and long term outcomes after alcohol septal ablation in patients with obstructive hypertrophic cardiomyopathy: data from China

 

ASA

NOHCM

p value

(n = 233)

(n = 297)

Age, y (SD)

48.7 (9.8)

46.2 (13.6)

0.018

Male, n (%)

149 (63.9)

210 (70.7)

0.112

NYHA class III/IV n (%)

183 (78.5)

11 (3.70)

<0.001

CCS class III/IV n (%)

79 (33.9)

11 (3.70)

<0.001

Syncope/presyncope n (%)

113 (48.5)

27 (9.4)

<0.001

Atrial fibrillation, n (%)

20 (8.6)

50 (16.8)

0.009

Prior stroke/TIA, n (%)

6 (2.6)

9 (3.0)

0.798

Diabetes mellitus, n (%)

11 (4.7)

21 (7.3)

0.272

Hypertension, n (%)

67 (28.8)

91 (31.7)

0.503

Coronary artery disease, n (%)

21 (9.0)

34 (11.9)

0.318

LAD, mm (SD)

41.3 (6.1)

39.6 (7.0)

0.002

IVS, mm (SD)

20.8 (4.9)

21.0 (6.6)

0.740

LVEDd, mm (SD)

41.8 (5.2)

44.7 (5.7)

<0.001

LVEF, % (SD)

71.6 (7.9)

65.4 (8.2)

<0.001

LVOTPG, median (IQR), mm Hg

93.5 (38.1)

 

<0.001

Baseline medications n (%)

   

Beta-blocker

193 (82.8)

258 (86.9)

0.220

CCB

64 (27.5)

70 (23.6)

0.316

  1. ASA, alcohol septal ablation; NOHCM, non obstructive hypertrophic cardiomyopathy; NYHA, New York Heart Association; CCS, Canadian Cardiovascular Society; LAD, left atrial diameter; IVS, intra-ventricular septal thickness; LVEDd, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; LVOTPG, left ventricular outflow tract pressure gradient; SD, standard deviation; CCB, calcium channel blocker.
Back to article page